On May 14, 2025 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that it filed a regulatory application with the Ministry of Health, Labour and Welfare (MHLW) for the anti-cancer agent/humanized anti-PD-L1 monoclonal antibody Tecentriq Intravenous Infusion [generic name: atezolizumab (genetical recombination)] for an additional indication of thymic carcinoma (Press release, Chugai, MAY 14, 2025, View Source [SID1234652973]). Tecentriq received orphan drug designation for this indication from the MHLW on March 31 this year, and the applications will be reviewed under priority review.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Thymic carcinoma is a rare cancer with poor prognosis after recurrence, and there is a need for new treatment options. We are working to obtain approval so that Tecentriq that demonstrated favorable efficacy in combination with standard chemotherapy can be delivered to patients as soon as possible as a new therapeutic option for thymic carcinoma," said Chugai’s President and CEO, Dr. Osamu Okuda.
This filing is based on the results from a phase II MARBLE study initiated by investigators, which evaluated the efficacy and safety of Tecentriq in combination with carboplatin and paclitaxel as first-line treatment for patients with unresectable thymic carcinoma. In this study, the overall response rate, which was the primary endpoint, was 56.3% (95% CI: 41.2-70.5). Common adverse reactions included peripheral sensory neuropathy, alopecia, constipation, anemia, decreased white blood cell count, nausea, maculopapular rash, neutropenia, decreased neutrophil count, decreased appetite, fatigue, and arthralgia. The safety profile observed in this study was consistent with the known safety profiles of each drug.
Chugai Pharmaceutical, a leading company in the oncology field, remains committed to addressing unmet medical needs in cancer treatment with innovative medicines, supporting patients and healthcare professionals.
About MARBLE study1
MARBLE study (jRCT2031220144) is a Japanese Phase II, multicenter, open-label, single-arm study led by physicians to evaluate the efficacy and safety of Tecentriq in combination with carboplatin and paclitaxel in patients aged 20 years or older with unresectable or advanced recurrent thymic carcinoma. The study evaluated safety and efficacy in 48 patients. The primary endpoint was overall response rate, and secondary endpoints included progression-free survival, overall survival, and safety.
About thymic carcinoma
Thymic carcinoma is a type of thymic epithelial tumor that originates from the thymic epithelium, which plays an important role in T-lymphocyte maturation, and is characterized by cellular atypia. The annual incidence in Japan is estimated to be 0.29 per 100,000 people2. The prognosis for unresectable cases is poor, highlighting the need for new therapeutic options.
About Tecentriq
Tecentriq is a cancer immune checkpoint inhibitor targeting PD-L1, which is a protein expressed on tumor and tumor-infiltrating immune cells. PD-L1 blocks T cell activity by binding with PD-1 and B7.1 receptors on T cell surface. By inhibiting PD-L1, Tecentriq may enable the activation of T cells and boost immune response against cancer cells. In Japan, Tecentriq was launched in April 2018 and has obtained approval for 5 indications (extensive-stage small cell lung cancer, non-small cell lung cancer, breast cancer, hepatocellular carcinoma, and alveolar soft part sarcoma).
Trademarks used or mentioned in this release are protected by law.